Form 4: NeoGenomics Director Neil Gunn Reports Equity Transactions
Statement of Changes in Beneficial Ownership
Director Neil Gunn acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.
Summary
- Director Neil Gunn acquired 23,077 shares of common stock on June 1, 2026, via the vesting of restricted stock units (RSUs).
- Following the transaction, Gunn holds a total of 51,177.31 shares of common stock directly.
- The director was granted new equity compensation, including 11,069 stock options at a strike price of $10.52 and 15,970 RSUs.
- The new equity grants have a vesting commencement date of June 1, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation and does not signal a change in company strategy or financial health.
Positives
- Director maintains a significant direct equity stake in the company, aligning interests with shareholders.
Negatives
- None noted; this is a standard equity compensation and vesting event.
Risks
- Equity-based compensation is subject to market volatility, which may impact the future value of the director's holdings.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that routine equity vesting and annual grants for board members are standard corporate governance practices in the biotechnology and diagnostics sector, reflecting typical retention strategies for independent directors.
Comparison to Industry Standards
- The equity compensation structure is consistent with standard practices for mid-cap healthcare companies.
- Director ownership levels are typical for non-executive board members in the diagnostics industry.
Stakeholder Impact
- Minimal impact on shareholders as these are standard equity compensation awards.
Next Steps
- Vesting of new RSU and option grants scheduled for June 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/01/2026 | Date of RSU vesting and new equity grant transaction. |
| 06/03/2026 | Date of filing. |
Keywords
NeoGenomics, NEO, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.